The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year


About Diagnostic Lab Corporation

Diagnostic Lab Corporation is a food and agriculture safety holding company. Utilizing multi-strategies, proprietary food technology and medical science, Diagnostic Lab Corporation ensures product quality, safety and truth in labeling for all ingestible products including medical and recreational cannabis.

Diagnostic Lab Corporation Headquarter Location

560 Sylvan Ave Suite 3160

Englewood Cliffs, New Jersey, 07632,

United States

(210) 500-9897

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Diagnostic Lab Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Diagnostic Lab Corporation is included in 1 Expert Collection, including Cannabis.



3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Latest Diagnostic Lab Corporation News

Grapefruit USA, Inc. Issues Update on Proposed Strategic Acquisition

May 9, 2022

Grapefruit USA Inc. LOS ANGELES and DESERT HOT SPRINGS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Grapefruit USA, Inc. (OTCQB: GPFT) (“Grapefruit” or the “Company”), an innovative California-based cannabiotech company, is providing an update on its previously announced execution of a Memorandum of Understanding (“MOU”) with Diagnostic Lab Corporation of Englewood Cliffs, New Jersey, (“DLC”) a diversified food and agriculture safety company, concerning Grapefruit’s acquisition of DLC. The Company and DLC (the “Parties”) have been in regular discussions since the execution of the MOU concerning the terms and timing of the proposed acquisition. The Parties have developed a plan pursuant to which Grapefruit will acquire substantially all of the assets of DLC which are necessary for the ongoing business of DLC and its affiliates. The Parties’ plans to obtain financing of $12.5 million, $7 million of which has already been committed, to build out its “Mothership” state of the art cultivation and laboratory center on the Company’s property at the Coachillin Industrial Cultivation and Ancillary Canna-Business Park (the “Coachillin Park”). The remaining funds will be utilized for the DLC asset purchase which will be acquired for a combination of cash and stock, to seek a 510K approval from the FDA for Grapefruit’s proprietary Hourglass™ THC/Cannabinoid delivery cream, initiate a series of acquisitions of synergistic testing labs, and for working capital and loan interest reserves. The Parties plan to retire the debt through a public equity raise and concurrent uplist to a U.S. or Canadian exchange. Bradley J. Yourist, Grapefruit’s CEO and co-founder, commented, “As previously announced, these will be the next steps in Grapefruit’s evolution into a medical science-based cannabiotech company which will develop and obtain regulatory approval for an ever-expanding line of proprietary Hourglass technology-based cannabis products. The build out of the ‘Mothership’ cultivation and lab facility at the Coachillin Park will guarantee a reliable source of reasonably priced pharma quality cannabis flowers to provide the base for non-hemp Hourglass products and for distribution in both the U.S. and Canada, when appropriate. Obtaining the 510K approval for the Hourglass technology will facilitate its rapid market acceptance. Our lab acquisition program will provide rapid revenue growth and expand the Company’s cannabis industry expertise. The Parties expect to execute and announce a binding letter of intent before the end of May 2022.”      For additional information about Hourglass Canada, please visit: To purchase Grapefruit’s groundbreaking CBD delivery relief cream outside of Canada, please visit: To learn more about Grapefruit’s new sustained-release Hourglass™ THC + Cannabinoid Topical Delivery Cream, please watch this promotional video: and visit our website at:

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.